SEC Comment Letter for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883) (BCLI) — Jan 12, 2012
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) (CIK 0001137883)
Date: Jan. 12, 2012 · CIK: 0001137883 · Accession: 0000000000-12-002051
AI Filing Summary & Sentiment
Reasoning
Letter
January 12, 2012 Via E-mail Liat Sossover Chief Financial Officer Brainstorm Cell Therapeutics, Inc. 605 Third Avenue, 34 th Floor New York, NY 10158
Re: Brainstorm Cell Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2010 Filed March 31, 2011 File No. 0-54365
Dear Mr. Sossover:
We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Joel Parker Joel Parker Accounting Branch Chief
Show Raw Text
January 12, 2012 Via E-mail Liat Sossover Chief Financial Officer Brainstorm Cell Therapeutics, Inc. 605 Third Avenue, 34 th Floor New York, NY 10158 Re: Brainstorm Cell Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2010 Filed March 31, 2011 File No. 0-54365 Dear Mr. Sossover: We have completed our review of your f iling. We remind you that our comments or changes to disclosure in res ponse to our comments do not for eclose the Commission from taking any action with respect to the company or th e filing and the company may not assert staff comments as a defense in any proceeding ini tiated by the Commission or any person under the federal securities laws of the United States. We urge all pers ons who are responsible for the accuracy and adequacy of the disclosure in the fi ling to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require. Sincerely, /s/ Joel Parker Joel Parker Accounting Branch Chief